Day 1: December 4, 2024
08:00-8:30- Registration & Refreshments
08:30-08:45-Welcome and introductions: Amir Seyedmousavi, USA & Malcolm Richardson, UK
Session 1:
- 08:45-09.00 Case study 1: Why it’s important to know local epidemiology of fungal infections? John Bennett, USA
- 09:00-09:30-Opportunistic fungal disease in normal and abnormal hosts, ICU patients, and children: underlying risk factors: John Perfect, USA
- 09:30-10:00-Global burden of fungal diseases (updates on Latin America, African countries, Europe and Asia): Arnaldo Colombo, Brazil
- 10:00-10:30-Fungal nomenclature (medically important fungi): Amir Seyedmousavi, USA
- 10:30-10:45-WHO fungal priority list and other emerging fungal pathogens: Ana Alastruey, Spain
10:45-11.00: Comfort Break
Session 2:
- 11:00-11:15-Case study 2: Why is it important to collect specimens properly if fungal diseases are suspected?: Juan Gea-Banacloche, USA
- 11:15-11:30-Clinical sampling, Processing and Direct microscopic examination: Arunaloke Chakrabarti, India
- 11:30-12:00-Cytology and histopathology: Gary Procop, USA
- 12:00-12:30-Detection of Pneumocystis pneumonia in HIV associated and non-HIV patients: Riina Richardson, UK
12:30-1:30: Lunch
Session 3:
- 1:30-2:00-Case study 3: Importance of species level identification: Shawn Lockhart, USA
- 2:00-2:30-Diagnostic work up for yeast infections: Malcolm Richardson
- 2:30-3:00-Diagnostic work up for mould infections: Cornelia Lass-Flörl, Austria
- 3:15-3:30-Diagnostic work up for dimorphic fungal infections: Nathan Wiederhold, USA
3:30-3.45-Comfort Break
Session 4:
- 3:45-4:15: Fungal molecular testing, and how to use next-generation sequencing in clinical laboratory: Lewis White, UK
- 4.15-4:45: Benefits and Limitations of MALDI-TOF for fungal identification: Darius Armstrong-James, UK
- 4:45-5:30-Daily Review, Q@A: Amir Seyedmousavi, USA & Malcolm Richardson, UK